CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | MicrobiomeTrials
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-15Est. Completion: 2030-01-31
Enrollment target: 20 participants
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States